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Thebeliefthat scenng test forteratogenicity areoflow predictive value has many si
0 ~~~who point to the Inconsistency wth which malformations are induce. However, to faul
systems whe such inconsisteny is predictale from both the inherently unstable nature
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upporters
It the test
ofa mal-
formation and from damentalprinciples ofteratology, is unrealistic,and, as is shown,perhaps
thegreaterfaults lie withthecritics.
itissuggested byexamples tht,ifattention was concentrated not on the inconsistent malforma-
tions but on more consitent embryopathic effects which in one form or another are always asso-
ciated with malfornations, the predictive value of the screening tests would appear in a more
favorable lgt. Thus, even if malformations are not demonstrated, the range of conditions
4doanges) in which they might occur can be detennined. Such infornation, used in conjunction
with that obtained from other preAlinic studies, can then form a reasonably sound basis for ex-
trapolation to man.
The title of this session suggests this paper
should discuss the detection of teratogens, but
there seems little profit in this, as the subject has
been discussed by everyone who is anyone, every
year since 1960.
Should I simply agree with the general opinion
that teratogenic tests are of a low predictive
value for the conclusive demonstration of
teratogenicity? After all, from the fundamental
principle that a malformation represents an un-
stable condition balanced on a knife edge between
relatively normal life and death, it'is obvious that
any number of small factors can tip the balance
one way or another. Consequently, even given
the mythical, ideal model system, or allowed
unrestricted experimentation with pregnant
women, looking for teratogens would be worse
than looking for a very small needle in a very
large haystack.
Then again, what would it mean if we found a
foolproof method of detecting teratogenicity?
Would it just confirm Karnofsky's law, that any
compound can be teratogenic if given to the right
species at the right dosage at the right time? Cer-
tainly no one seems to worry that we continue to
eat salt, despite the fact that it can cause em-
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bryotoxicity and teratogenicity in mice; pregnan
women still go to the beach, although sand grain
cause malformations in chick embryos; and we al
breathe oxygen, though it can cause cataracts i;
premature babies and perhaps may also be im
plicated in increased incidences of patent ductu
arteriosus in some localities.
At increasingly subtle levels, there exists
host ofteratogens-illogically referred to as fals
positives-which are used in man because th
situations in which teratogenicity occurs are ex
tremely unlikely to arise in practice. For exam
ple, because cortisone causes cleft palate only i
mice, corticosteriods are considered fals
positives, yet the more powerful fluorinated cox
ticosteriods will cause the same kinds of malfox
mation in a wide variety of species, includin;
primates (1). Trypan blue is called a false positiv
because in rodent species it acts on the yolk sa
not present in man; however, as shown by Beclh
(2), trypan blue also causes malformations i
ferrets which, like man, do not have a yolk sa
placenta. Who would dare to say what would har
pen if we tested these compounds in man to th
same degree that we do inanimals?
Thus our real question is not whether
material is teratogenic but whether it will con
stitute a teratogenic hazard when introduced int
the human environment. To answer this second
December 1976 9'more pertinent question requires not one, but
several investigations, to determine possible
beneficial or adverse reactions that may occur.
After this exercise, the combined results are
assessed to determine whether or not the cir-
cumstances required for the beneficial effects
coincide with the circumstance in which adverse
effects occur.
This second stage in the progess can be likened
to building up a jigsaw puzzle (to create a profile
of biological activity.) In some cases, a few pieces
may give a clear indication of the overall picture;
in others, one may have to wait until the last
piece falls into place. In this analogy, the
teratogenic tests are but one or two small pieces
fitting into a section of reporductive toxicology
which in turn must be fitted into the larger
framework before their significance can be deter-
mined.
As an example of the technique, consider the
frequently repeated statement that thalidomide
would not be detected by current methods. This
is a narrow view, based on the negative or doubt-
ful indications of teratogenicity in rats and mice,
as on building up the total picture, the low
pregnancy rate, low litter size, and poor viability
of the few litters obtained in the fertility study
(Table 1) would have provided a jarring note
against the negative teratogenic and con-
ventional toxicity studies.
Another shock would have arisen from the oc-
currence of embryotoxicity and a high malfor-
mation rate in the rabbit teratology study. The
warning given by these awkward pieces of the
jigsaw would (or should) have called for further
investigation which in these days would quite
likely include a primate study leaving no doubt of
thalidomide's unique potential (3). Thus, it is
evident that, if used correctly, the current tests
can indicate the hazard of a teratogen even if,
initially, they cannot prediet itsteratogenicity.
With this in mind, I would now like to examine
the section of our jigsaw required for testing new
drugs to determine their potential effects on
development (4).
The current system employed by most coun-
tries is the three-segment design which for the
FDA consists of (I) studies offertility and general
reproductive performance: (both sexes treated
continuously from premating through to the end
of lactation, one species); (II) studies of
teratogenicity and embryotoxicity (pregnant
females treated duringembryonic organogenesis,
two species); (III) peri- and postnatal studies
(pregnant females treated during late fetal
Table 1.Effect ofthalidomide in thetwo-littertet.
Mating
Observa- Treat-.--....- - - _ ---_--
tion ment Experiment 1 Experiment 2
1st 2nd Ird 1st 2nd 3rd
Conception Control 79 74 83 50 62 75
rate, % Thalido- 32 17 6 5 0 0
mide
(200
mg/kg!
day)
Litter size Control 8.3 8.9 8.8 9.2 9.5 9.8
atbirth Thalido- 3.5 4.7 3.0 4.0 0 0
mide
(200
mg/kg/
day)
development through parturition to the end of
lactation, one species).
Segment 1: General Fertility and
Reproductive Performance
The most widely known general reproductive
study, is that of the FDA (Fig. 1). It is con-
ventionally performed in rats, although often it
would be equally valid and more economical to
usemice, hamsters, or gerbils.
One control and two test groups, each con-
taining 10 males and 20 females, represents a
basic minimum. In the U. K., the basic minimum
is 12 males, 24 females, and three test groups,
which in the long run proves more economical
because of the reduction iln problems at later
stages of assessment. Treatment continues
throughout the study after starting 60 days prior
to mating for males and 14 days prior to mating
for females; a more common variation is to per-
form two tests, treating the males in one and
females in the other. After mating, 10females per
group are killed and examined at mid-pregnancy,
for the detection of early effects on implantation
and embryonic development. In the UK thissacri-
fice is delayed to day 20 of pregnancy on the
-t.rli .. C.,'..-
FIGURE 1. Fertility andgeneralreproduction study.
Environmental HealthPerspectives 98,theory that it will allow examination of fetuses
for malformations. The remaining females in each
oup are allowed to bear and rear their young
for 21 days to detect effects occurring during late
gestation and lactation.
In the UK and to a lesser extent in the USA
ere have been recommendations that the study
be extended by rearing some of the young to
aturity in order' to detect latent effects on
behavior, physiological development, and
reproductive capacity. However, practical ex-
perience suggests, that introduction of this ex-
Fitension on a routine basis will mostly result in
">wasted resources, since most compounds that
would induce latent effects would already have
-provided an indlcation ofactivity.
At present therefore, extensions would appear
to be best confined to instances with a priori
eIvidence that the extension would be in-
formative, i.e., for steroids, compounds affecting
the neuroendocrine system, addictive drugs, and
perhaps certain antibiotics ofthe types known to
induce deafness.
There are a number of design faults in the
fertility study which can lead to malpractice. The
prolonged treatment period of the male is often
incompatible with the concurrent recom-
mendation that compounds be administered by
the intended clinical route and that the highest
dosage should cause minimal interference with
the parental economy. Difficulties particularly
arise with unusual routes of administration such
as inhalation and instillation into eyes, nose and
other body orifices. It is impracticable in the rat
to make daily intravenous injections for longer
than 4 weeks and impossible with the hamster.
Two other risks associated with prolonged
treatment are that subtle cumulative adult
toxicity may provoke secondary effects in the
later, critical stages of investigation and that the
development of detoxification mechanisms and
tolerance (which can occur to a marked extent in
rats) could mask effects that would arise by de
novo treatment during fertilization and early em-
bryonic development.
The shorter two-week premating period of
females avoids some of the difficulties, but in
many cases it is usually too short to demonstrate
either tolerance or cumulative toxicity
adequately.
The next pitfall in the reproductive study is the
interim sacrifice, which together with the fact
that only 10 or 12 males are used effectively
reduces comparable group size to 10 on most oc-
casions. Thus, given an all-or-none response, such
as nonpregnancy, or total litter loss, then, by the
laws of probability, statistical significaince would
be attained only if 40-50% of animals were af.
fected (Table 2).
The importance of this is, that, in practice, the
most common primary effect ofhighly active com-
pounds is the general nonspecific response ofnon-
pregnancy. For example, not only is non-
pregnancy the primary effect of the teratogen
thalidomide (Table 1), it is also the primary
response to haloperidol (Table 3), which affects
mating; in turn the effect on mating masks the
fact that. haloperidol can cause delayed im-
plantation and possibly also affects later
physiological development.
Nonpregnancy or, more precisely, pseudo-
pregnancy is the predominant response tc
guanethidine-like hypotensives, which cause a
reversible failure in ejaculation.
Thus, with widely different actions and dif
ferent hazards, we encounter the same response:
i.e., nonpregnancy; therefore, we can anticipate
the same response with many compounds. But.
unlike these highly active compounds, thE
majority of materials examined in practice are
not highly active and, more likely, will give bor
derline results if any. In these circumstances tht
necessity to obtain a 40-50% difference to be cer
tain ofan effect seems somewhat insensitive.
Table 2. Significance ofdiffereces n pregnancy rate
with 10animals pergroup.
Test groupsuccess
Exact test atp<0.05
Control success One-tailed Two-tailed
No. % No. 9 No. %
10 100 6 60 5 50
9 90 4 40 3 30
8 80 3 30 2 20
Table 3. Effect ofhalopenrdol in two-littertest.
Conceptionrate, %
Treatment Continuous dosing Withdrawal for a
duringmating 7 daymatingperio4
Control 79 79
Haloperidol 22 44
0.1 mg/kg
1.0mg/kg 0 39
5.0 mg/kg 0 12
December 1976 9!-Segment II:Teratology Studies
Teratology studies are by far the best known
and most widely performed studies in reproduc-
tive toxicology. Basically, requirements call for
studies in two species, treatment being applied
during the critical phases of organogenesis. This
is transposed chronologically to days 6 to 15 of
pregnancy in rats and mice and days 6 to 18 of
pregnancy in rabbits. (Fig. 2).
In the USA, one control and two test groups
each containing 20 rats and mice or 10 rabbits,
represents the basic minimum; in the UK and
several European countries, three test groups
are required. Occasionally, other species may be
used, and for larger ones such as pigs, primates,
and dogs, smaller group sizes are allowed. The
reasons for this are entirely economic and com-
pletely unscientific.
uo.
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FGIGURE 2. FDA segment 2: teratology studies.
Fetuses are usually delivered by hysterectomy
one or two days prior to parturition; the numbers
oflive young and embryonic deaths are recorded.
Fetuses are also weighed and examined for ex-
ternal, skeletal, and visceral malformations.
I believe that the design of segment II study is
essentially correct for general purposes. That
this is sometimes doubted, is mainly due to
misuse and misinterpretation (5). Why these
human errors should occur is due to many
reasons, but one of the most common is failure to
remember the basic principle that malformations
may be induced only under precise conditions,
particularly oftiming and dosage. (6).
Thus, because a relatively few, highly active
teratogens are consistently shown by the
published literature to provide high rates of ob-
vious malformations, it is believed that all one
has to do to determine teratogenicity is to ad-
minister a material to a few pregnant animals.
This is not the case, because for new com-
pounds there are no prevlously published guides
to the precise optimum conditions for obtaining
malformations; moreover, most compounds that
are tested have a low potential for causing
malformations. Consequently, the chances of ob-
taining malformations at a rate high enough to be
distinguished against the normal background are
extremely remote.
Perhaps, therefore, it would help if we stopped
calling these studies teratogenic tests and used
the term, "tests for selective embryopathy" or as
Wilson puts it, testsfordevelopmental toxicity."
There are several advantages for de-
emphasizing the search for teratogenicity. First,
it reminds us that we are interested in detecting
hazardous materials. In this respect it is just as
important to detect embryolethality, retardation
of fetal growth, or even increased maternal
toxicity (as occurs, for example, with many anti-
inflammatory agents or iron dextrans). In other
words, we are looking for any effects that would
reduce the safety margin predicted by other
toxicity tests.
Another advantage of de-emphasizing
teratogenicity is that more consistant, ob-
jectively determined parameters, such as mater-
nal and fetal weight or numbers of live and dead
young, are used to determine whether activity is
present. Moreover, in approachingthe testin this
manner we do not reduce the risk of failing to
detect hazardous teratogenic compounds. The
reason for this is that the unstable, inconsistent
nature of a malformation also ensures that other
effects occur. For example, most classic tera-.
togens-including the unique thalidomide-will
cause embryonic death at the same dosages as
those causing malformations (Figs. 3 and 4). Also,
all species show a number of variations and
anomalies which, because they are less detrimen-
tal to survi'val, occur in more measurable num-
bers than major malformations. Thus changes in
their incidence due to teratogenic activity can be
more readily analyzed. The effect of aspirin on
the incidence of extra ribs in the rat provides a
classic example with its significant dosage-
related trend (Table 4). Interestingly, changes in
the incidence ofthese variations are commonly in-
duced at dosages below those causing frank mal-
formations, possibly because some of them are
the results of compensatory mechanisms invoked
to halt the progress to malformation and death.
Even in the extremely rare instance where em-
bryolethality is not encountered, other clues do
exist; for example, with one unique rat teratogen
there was a reduction in fetal weight (Table 5).
Environmental Health Perspectives
a G I 0 20
e .... *M MATERNAL LD5O
*.. LITTER ioo% RESORBED
- LITTER L05o E3 TERATOGENIC RANGE
B-LOW LITTER LO5Q
--- LITTER 100% NORMAL
-FIGURE 3. The narrow
1 ,f.I
range of
effects.
dosages for teratogenic
/
/
FIGURE 4. Thalidomide dose response:(- -) maternal toxici-
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Table 4. Effeet ofaspirin on the incidence ofextra ribs in the
CDrat.
.........
Dosage, mg/kg-day Pups with extraribs, %
0 10
150 58 a
300 98*
a p>0.001
The unique nature of this teratogen was the ab-
sence of the embryolethality shown by classic
teratogens (Fig. 3).
On a cautionary note, I must point out that the
reliability of these other indicators of em-
bryopathy stem from the use of repeated dosing
and several dosages in screening tests, and they
may not be so readily induced, nor so necessary,
in the single-dose studies ofclassicteratology.
In using the tests to determine selective em-
bryopathy I can think of no better principles to
follow than those outlined by WHO and the
Canadian government (7, 8).
Two of the main factors in these recom-
mendations are that materials should be ad-
ministered by the intended clinical route (where
possible) and that dosages shfould be set as
follows: (1) the highest dosage should cause a
minimal interference with maternal economy
(i.e., minimal toxicity); (2) the lowest dosages
should preferably cause a clinical (phar-
macological) response in the test species; and (3)
one or two intermediate dosages should be
logarithmically situated between higher and
lower dosages. Obviously, it will not always be
possible to follow these guidelines to the letter,
but with common sense the intent can be
followed.
A clinical effect may be difficult to show, soit is
best to come down in logarithmic sequence from
the high dosage. If the test material has a short
half-life, it may be advisable to give several doses
in one day; with a depot preparation perhaps at
intervals of one or more days. Where cumulative
toxicity or rapid development oftolerance occurs,
one may have to dose for a shorter period and
double up the study to cover the whole suscep-
tibleperiod oforganogenesis.
If neither clinical nor toxxic effects can be ob-
tained by routes allowing administration of very
large doses, one should question whether the
material is active or whether the correct species
is being used. The term minimal toxic effect
should be interpreted broadly and should include
extended pharmacological activity. Do not set
dosages for repeated dose studies as arbitrary
multiples of the single dose LD3o value; the
results can be fatal, literally as well as figurative-
ly. For example, in an ESSDT cooperative study
(8), several laboratories tested Myleran, using
repeated daily dosages of 1/3, 1/9, and 1/27ofthe
single dose LD&D. Given the nature of the test
material it is hardly surprising that most animals
at the highest two dosages died and that there
were many instances of total litter loss at the
lower dosages (9).
Having set up the study as a test for selective
embryopathy, it is important to assess the results
from the same direction, and one of the ways to
do this is to examine the pattern and type of dose
response. One relatively rare type is the oc-
currence only of maternal toxici-ty, usually death.
This contains no real risk of teratogenicity but it
is advisable to compare with other studies to
determine whether pregnancy has altered the
level of adult toxicity. The next type of response
occurs very frequently, and in this pattern there
is increased embryotoxicity but no
teratogenicity. More often than not, the em-
December 1976 101bryotoxicity is a secondary consequency of
maternal toxicity which can often be indicated by
distinct "all-or-none" litter effects. When the em-
bryonic response is close to the maternal respon-
se there is no alteration in the predicted safety
margin but, if there are marked differences bet-
ween embryotoxic and maternal toxic dosages,
you have either a dangerous material or a
marketable abortifacient.
Usually more than one test is required to
distinguish this response from the nextmost com-
mon one, which occurs with teratogens. This
example (Fig. 5) refers to aspirin but could apply
equally to many others, especially the classic
teratogens. With this pattern a teratogenic zone
occurs just below, or overlapping the dosages
causing maternal toxicity. Naturally, with the fir-
st dosages chosen, the optimal- dosages for
teratogenicity may not be encountered, but,
because of the associations between malfor-
mations and other effects, one knows the range to
be explored with a second study. With this type
ofresponse one would refer to other studies such
as pharmacology or pharmacokineties to ensure
that there was suffi'cient margin between the
clinical dosage and the lowest no-effect dosage in
the teratology study. Alternatively, as with an-
f'/0 effect
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ticancer agents, one would need to be assured
that the benefits of treatment would justify ap-
proachingateratogenic zone.
Finally, the dose response of thalidomide (Fig.
4) shows a potential high risk situation.
Teratogenicity and embryotoxicity have occurred
at much lower dosages than maternal toxiiety, in-
dicating selective embryopathy and totally
altering the safety margin predicted by other
studies.
Segment Ill: Pennatal and Postnatal Study
Completing the three-segment design is the
perinatal and postnatal study (Fig. 6). Basically
20 female rats per group are treated during the
last quarter of pregnancy and through lactation.
Litter parameters such as growth and develop-
ment of young are examined from birth through
lactation to weaning, at which time animals are
killed and examined. In the USA a minimum of
two test groups is employed, but the use of three
test groups and a control as recommended by the
UK and Sweden is preferable.
The virtue of this study is the simplicity of
design since it confers great flexibility in in-
troducing the small modifications to make it
suitable for a particular test material. The study
can be transformed readily to a variety ofspecies,
including dogs, pigs, and primates. It can also be
modified into a cross-fostering study to distin-
guish between direct and maternally mediated ef-
fects. It is easier than the fertility study to ex-
tend for investigation of late development
effects.
Perhaps, the values ofthis test are not fully ap-
preciated unless it is designed and performed in
conjunction with the fertility and teratology
studies. My best example of this concerns the
potent rat teratogens mentioned earlier (Table
5). With this agent a high neonatal mortality rate,
in a form of perinatal and postnatal study,
provided the first indication that something was
wrong (Table 6). Cross-fostering studies showed
that the effect was on the fetus, not the parent,
and the teratology study subsequently revealed a
high incidence ofheart malformations.
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FIGIRE 6. Perinatal and postnatal study.
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ITable5. Unique teratogenicaction in rats.
Mean values per litter
No. of No. of Visceral
viable resorp- Fetal malforma-
1ouplitters young tions weight tion, %
1: 3 18 8.1 1.6 3.74 16.7
; 2 18 10.8^ 0.5 3.58 32.2
3 19 10.1 0.5 3.35 b 65.2 b
4 20 9.8 1.5 3.28 88.6
-*p<O.O5 Wilcoxon test.
,>'
0 C.01l. bp<0.O1.
Table 6. Effect ofteratogenic action on postnatalmortality
rate: mean values per litter.
At birth LS
X Atbirth at 21 days
postpartum,
Group Viable young Loss, % _
I (Control) 10.4 8.6 18.2
2 9.9 19.3 40.8
3 5.1 51.8
* 98.5 '
4 3.4 b 71.9
b 100.0
p<0.1O, Wilcoxon test.
P<0.00I.
p<0.05.
Conclusion
Having completed my description of the three-
segment design for reproductive toxicology it
may seem that I have strayed from the expected
path. Much of my waywardness is deliberate.
Many of the loose ends can only be tied up by
reference to other toxicological, pharmacological,
and pharmacokinetic studies, which reminds us
that for proper extrapolation, results must be
placed in the larger framework of biological ac-
tivity.
I have commented more on the way people per-
form and assess studies than on the animals or
techniques. Again this is intentional, because I
believe that many of the so called "faults" of the
test are in fact the faults of the investigators and
assessors; as just one example from many, Table
7 illustrates how incorrect analysis can make
"significant" differences out ofnothing.
Thus the only major design change I would
make at the present time would be to simplify the
general reproductive study by making it consist
of equal numbers of males and females per group
and omitting the interim sacrifice. Also it could
Table 7. Effect ofstatistical analysis based on incorrect sam-
ple units.
Mean fetal weight, g
Treatment Male Female
Control 5.2 5.4
Low dose 5.2 5.4
Highdose 5.3' 5.5'
Laboratory
standard
Control 5.3 5.6
range 4.8-5.9 4.9-6.0
p<0.01 (Anovar) usingfetal units instead of letter units.
be extended to a second generation to make it
suitable for pesticides and food additives.
Extension to a second generation may also
make it suitable for detecting late developmental
effects, as for general purposes at an initial
screening stage, I can think of no better guide to
whether an animal is functioning correctly than
that it will grow and reporduce. Improvement in
the predictive value of reproductive toxicity
studies will come, not from the introduction of
sweeping changes to the three segment design,
but from the eorrect application of minor mod-
ifications applicable to the individual test com-
pound, and from a greater understanding of the
role of initial screening tests. We should also
revert back to following the intent of the guide
lines rather than the letter.
No one has found the pot of gold at the end of
the rainbow nor, will you find an ideal test system
to provide all the answers in one go. Therefore
the screening tests should not be considered as an
end point but as a starting point. In some cases
the results together with those of other studies
will justify the risk of performing the definitive
experiment in man. In other cases, the pieces of
our jigsaw may not fit as well, and further inves-
tigations will be required before our definitive
study in humans.
Thus, rather than complicate initial screening
tests, greater use should be made of secondary
stage investigations. By this time, the test com-
pound is not so new, there are clues to indicate
the best types of investigation, and there is a
familiar framework to establish the perspective
of results obtained by more sophisticated meth-
ods. Because of these factors, the deficiencies of
more specialized techniques can be covered and
they can be used to more telling effect. For exam-
ple pig and primate teratology studies, studies of
mechanisms of action, special pharmacokinetic
studies in the mother and embryo, and, I suspect
December 1976many of the suggested behavior studies, are usu-
ally more appropriate at this stage than at initial
screening stage.
Many sophisticated techniques have been de-
veloped by using compounds of known potential.
Overzealous transference of these techniques to
the routine initial screening stage of new com-
pounds could lead to their inappropriate usage
and thereby their devaluatioz. The approach to
initial screening must be different to that for sec-
ond and third level investigations. Initial screen-
ingtests must be simple and robust and provide a
broad basis from which more precise and defini-
tive studies can be launched along the lines in-
dicated by the initial results.
REFERENCES
1. Hendrickx, A. G.. et al. Teratogenic effects oftriamcinolone
on the skeletal and lymphoid systems in nonhuman pri-
mates Fed. Proc. 34: 1661 (1975).
2. Beck, F. Comparative placental morphology and function.
Environ. Health rp. 18:( 6-1977).
3. Delahunt, C. S., and Lassen, L..J. Thalidomidesyndrome in
monkeys. Science 146:649 (1964).
4. Palmer, A. K. Some thoughts on reproductive studies for
safety evaluation. Proc. ESSDT 14: 79 (1972): Exerpta
Medica ICSNo. 288.
5. Palmer. A. K. Problems associated with the screening of
drugs for possible teratogenic activity. In: Experimental
Embryology and Teratology, Vol. 1 D. N. M. Woollam and
G.Morris,Eds.,Elek,London, 1974, pp. 16-33.
6. Wilson, J. G. Embryological considerations in teratology.
In: Teratology: Principles and Techniques. J. G. Wflson
andJ. Warkany, ChicagoPress, Chicago, 1964.
7. World Health Organization. Principles for the Testing of
Drugs for Teratogenicity. WHO Tech. Rept. Series, No.
364, Geneva, 1967.
8. Anonymous-The Testing ofChemicals forCartinogenicity,
Mutagenicity Teratogenicity. Canadian Ministry of Health
and Welfare, Ottawa, 1973.
9. ESSDT. The evaluation of drugs for foetal toxicity and
teratogenicity inthe rat. Proc. ESSDT 7: 216 (1966).
104 EnvironmentalHealth Perspectives